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Blood-Based Biomarkers
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Abstract Introduction: A blood-based biomarker panel to identify individuals with preclinical Alzheimer’s
disease (AD) would be an inexpensive and accessible first step for routine testing.
Methods: We analyzed 14 biomarkers that have previously been linked to AD in the Australian Im-
aging Biomarkers lifestyle longitudinal study of aging cohort.
Results: Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy
controls at baseline and 18 months (P 5 .0003) and chemokine-309 (I-309) were increased in AD
patients compared to mild cognitive impaired individuals over 36 months (P 5 .0008).
Discussion: These data suggest that apoJ may have potential in the context of use (COU) of AD diag-
nostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for pro-
gressing towardAD. This work takes an initial step toward identifying blood biomarkers with potential
use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by extracellular deposition of amyloid b (Ab)
in senile plaques and intracellular formation of neurofibrillary
tangles of hyperphosphorylated tau protein. Although a small
percentage of AD patients carry specific mutations that cause
the disease at an earlier age, most patients are considered spo-
radicwith a later age of onset. For this subgroup, themajor risk
factor is the ε4 allele of the APOE gene. Currently, the defin-
itive diagnosis of AD can be performed only postmortemwith
the analysis of senile plaques in the brain parenchyma,
although positron emission tomography (PET) scan modal-
ities have received regulatory approval that can detect the
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presence of Ab among living individuals. Furthermore, the
search for biomarker panels has also been extended to cerebro-
spinalfluid (CSF) inADandother neurological diseases [1–3].
It is to note that the examination of CSF, which reflects more
closely what happens in the brain, has the disadvantage that
CSF collection requires trained people, it is associated with
a higher degree of risks, and it is not suitable for repeated
draws. Although PET and CSF biomarkers are currently the
gold standard to detect amyloid living patients, these
biomarkers are expensive and cannot be used in routine
clinical care. Blood-based biomarkers provide cost- and
time-effective methods that can be used as the first step in a
multistage neurodiagnostic process that would significantly
streamline and cost contain this novel strategy. Recent years
have witnessed an exponential increase in the investigation
ofblood-basedbiomarkers that have diagnostic andprognostic
potential in AD. The identification of blood-based biomarkers
that can identify groups that are at a higher risk for AD within
routine clinical care (e.g., within primary care clinics) before
the clinical manifestation would make possible targeted early
treatments aimedat postponing the onset of the clinical disease
itself. Such a paradigmwould be advantageous not only for the
individuals at risk, but also for the whole community, as
delaying the onset of the disease would lighten the economic
burden that is associated with the care of these patients.
In the recent years, several groups have published reports
that associate AD to a specific group of biomarkers that
largely focus on (1) discriminating between AD cases and
controls (i.e., putative “context of use” [COU] related to
AD diagnostics) or (2) predict the onset of the disease (i.e.,
putative COU related to AD prognostics). With regards to
diagnostics, Ray et al. [4] defined a group of 18 plasma
biomarkers out of a larger group of 120 analyzed that discrim-
inated AD from controls with high accuracy. Later in 2008,
research based on this 18 biomarker panel found that using
5 of these 18 was sufficient to differentiate between AD and
controls with the same accuracy [5]. However, two subse-
quent analyses of these 18 proteins in different cohorts [6,7]
failed to validate the biomarker panel finding significant
differences between AD and controls only in five and three
biomarkers, respectively. In 2012, the current group [8] iden-
tified a panel of 18 blood-based biomarkers that distinguished
between AD and controls with high accuracy in the AIBL
cohort and replicated the findings in the ADNI cohort. At
the same time, an independent group analyzed two cohorts
(TARC and ADNI) and found a panel of 11 biomarkers that
accurately discriminatedAD fromcontrols across both serum
and plasma [9], which was a continuation of their previous
work [10] in which a panel of 30 biomarkers was identified.
Another research group [11] reported that a panel of three
blood-based biomarkers was able to discriminate AD from
controls with a correct classification of more than 80%. In
2012, Johnstone et al. [12] reported a panel of 11 biomarkers
in ADNI cohort identified preclinical AD. Other groups have
performed similar analysis and identified a plasma biomarker
panel in AD [13]. Some other studies have also associated
blood-based biomarker panels withmicrovascular pathology,
brain atrophy, and cognitive decline in AD [14,15]. The
common problem in all these studies is the variability of the
biomarkers evaluated and the statistical analysis used to
determine the diagnostic and prognostic value of the panel
for AD with sufficient sensitivity and specificity. In this
study, a panel of 14 biomarkers that have been identified as
significant in 1 or more of the previous analyses was
selected for analysis using the well-characterized AIBL
cohort, baseline and longitudinal samples. These analyses
were undertaken with the goal of determining if biomarker
levels were different in AD compared with healthy controls
(HCs) and mild cognitive impairment across time points,
hence demonstrating their diagnostic value. In addition, if
these biomarkers were associated with brain Ab burden as
assessed by PET results suggesting that different levels may
be able to predict which individuals will convert to MCI/
AD.The longitudinal analysis inADpatientswas also carried
out to study whether these biomarkers were associated with
the progression of the disease.
2. Materials and methods
2.1. Population sample
2.1.1. The AIBL cohort
The cohort recruitment process including the neuropsy-
chological, lifestyle, and mood assessments have been previ-
ously described in detail [16]. In brief, the AIBL study
recruited a total of 1166 participants over the age of 60 years
at baseline, of whom 54 were excluded because of comorbid
disorders or consent withdrawal. Using the NINCDS-ARDA
international criteria for AD diagnosis [17] and symptomatic
predementia phase criteria for MCI diagnosis [18], a clinical
review panel determined disease classifications at each
assessment time point to ensure accurate and consistent
diagnoses among the participants. According to these
diagnostic criteria, participants were classified into one of
three groups; AD, MCI, or HCs. At baseline, there were a
total of 768 HCs, 133 MCI, and 211 AD subjects.
The AIBL study is a prospective, longitudinal study,
following participants at 18-month intervals. This particular
study reports on 711 individuals who completed the full
study assessment and corresponding blood sample collection
at baseline, 18 months and 36 months follow-up time points.
The institutional ethics committees of Austin Health, St.
Vincent’s Health, Hollywood Private Hospital, and Edith
Cowan University granted ethics approval for the AIBL
study. All volunteers gave written informed consent before
participating in the study.
2.1.2. Sample collection and APOE genotyping
Plasma was isolated from whole blood and collected in
standard EDTA tubes with prostaglandin E1 (33.3 ng/mL,
Sapphire Biosciences, NSW, Australia) added. On
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completion of blood fractionation, samples were aliquoted
and immediately stored in liquid nitrogen until required for
analysis. DNA was isolated from whole blood using a
QIAamp DNA Blood Midi Kit (Qiagen, VIC, Australia) ac-
cording to the manufacturer’s protocol, and APOE genotype
was determined through either polymerase chain reaction
(PCR) amplification and restriction enzyme digestions, as
previously described [19], or through TaqMan genotyping
assays (Life Technologies, Mulgrave, VIC, Australia) for
rs7412 (assay ID: C____904973_10) and rs429358 (assay
ID: C___3084793_20). For TaqMan assays, PCRs and real-
time fluorescence measurements were carried out on a
ViiA 7 real-time PCR system (Applied Biosystems, VIC,
Australia) using the TaqMan GTXpress Master Mix (Life
Technologies) methodology per manufacturer’s instructions.
2.1.3. Plasma biomarker assay
Aliquots were prepared according to the volume required
for each set of assays and stored at280C. All samples were
assayed in duplicate via a multiplex biomarker assay plat-
form using ECL on the SECTOR Imager 2400A from
Meso Scale Discovery (MSD; http://www.mesoscale.com).
The analytes requiring similar dilution were grouped
together in the multiplexing plate by the manufacturer.
The MSD platform has been used extensively to assay bio-
markers associated with a range of human diseases including
AD. ECL measures have well-established properties of
being more sensitive and requiring less sample volume
than conventional enzyme-linked immunosorbent assay,
the gold standard for most assays. The biomarkers assayed
were chosen from previously generated and cross-
validated AD algorithms from various biomarker studies
[8–10,20] and included the following: thrombopoietin
(TPO), interleukin-18 (IL-18), fatty acid binding protein
(FABP3), pancreatic polypeptide Y (PPY), chemokine
I309 (I309), serum amyloid A (SAA), C-reactive protein
(CRP), soluble vascular adhesion molecule 1 (sVCAM1),
soluble intercellular adhesion molecule 1 (sICAM1),
alpha-2-macroglobulin (A2M), beta-2 microglobulin
(B2M), Factor VII (FVII), adiponectin (adipo), apolipopro-
tein J (apoJ).
Plates were washed and blocked as per manufacturer
instructions using the supplied buffers. Samples were diluted
according to each respective assay group and applied to the
plate, along with standards. Plates were then sealed and
incubated at room temperature for 2 hours. Plates were
washed three times using phosphate buffered saline Tween
20 (PBST), then secondary detection antibodies were added
and plates were sealed and incubated for a further hour.
Plates were washed three times with PBSTand read solution
was added according to the assay instructions. Plates were
immediately read using an MSD plate reader. The supplied
software was used to determine standard curve and sample
concentration, according to 5-PL curve-fitting techniques.
The final protein biomarker concentration was reported in
pg/mL units.
2.1.4. Assessment of neocortical Ab via PiB-PET
A subset of the AIBL cohort (n5 287) underwent carbon
11-labeled Pittsburgh compound B–positron emission
tomography (11C-PiB-PET) imaging at baseline to measure
brain Ab burden, as previously described [21]. PET standard-
ized uptake value (SUV) data were summed and normalized
to the cerebellar cortex SUV values to obtain the region to
cerebellar ratio (standardized uptake value ratio [SUVR]).
A threshold of 1.5 SUVR was used to discriminate between
high (PiB1) and low (PiB2) brain Ab burden [22]. Of the
total 711 participants reported on here, 180 individuals
underwent PiB-PET imaging at baseline, 158 at 18-month
follow-up, and 120 underwent at 36-month follow-up.
2.1.5. Statistical methodology
Descriptive statistics including means, standard devia-
tions, and frequencies were calculated across clinical classi-
fications. Gender and APOE ε4 allele comparisons were
assessed using chi squared (c2) test and Fisher’s exact test
where necessary. Analysis of mean biomarker levels
between clinical classifications adjusted for age, gender,
and APOE ε4 allele status to assess the potential of these
proteins as biomarkers for AD was performed using
proportional odds logistic regression (for three group ana-
lyses, HC/MCI/AD as the outcome) and generalized linear
modeling (GLM, for two groups, HC vs. AD as the outcome,
binomial family). These statistical models were used as they
are able to assess the differences in mean biomarker levels,
adjusted for confounders under the assumption that there
is a certain level of uncertainty in the outcome (clinical clas-
sification is not 100% correct). P-values were compared a
Bonferroni adjusted alpha (a), with the number of bio-
markers tested as the adjustment factor (a 5 0.05/14,
0.00036).
For the longitudinal analyses, linear mixed-effects
modeling (LMM, using the biomarker as the [Gaussian]
outcome at each time point) was used to assess mean
biomarker levels over time for stable HC and AD groups
individually, adjusted for age, gender, site, and APOE ε4
allele status. Assessment of biomarkers longitudinally
between HC/MCI and AD groups was performed using
cumulative link mixed models (CLMMs) for the three group
clinical classification comparison, and the generalized linear
mixed models (GLMMs, binomial family) for the individual
group comparisons. GLM combined with receiver operating
characteristic (ROC) analyses were combined to perform
100-fold repeated random subsampling validation for
disease predictions.
Correlations between quantitative SUVR and all the bio-
markers were carried out using Spearman’s rank correlation
analysis (r). A cutoff value of 1.5 for SUVR was used as the
most appropriate criterion for biomarker evaluation. The R
statistical software environment, version 2.15 was used for
all statistical analyses (Team, R Development Core. 2009.
R: A Language and Environment for Statistical Computing
Manual).
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3. Results
3.1. Population demographics
Baseline, 18-month, and 36-month follow-up time points
demographic data, APOE ε4 allele status, and Mini–Mental
State Examination (MMSE) for the AIBL cohort are pre-
sented in Table 1. PiB-SUVRs for the AIBL imaging subco-
hort are also presented in Table 1. Plasma levels of
biomarkers (pg/mL) TPO, IL-18, FABP3, PPY, I309, SAA,
CRP, sVCAM1, sICAM1, A2M, B2M, FVII, adipo, apoJ
were assayed in 554 healthy controls, 65 participants with
MCI, and 92 participants with AD (total N 5 711 at base-
line). Age, APOE ε4 allele status, and MMSE were signifi-
cantly different between clinical classifications at baseline,
18 months, and 36 months (P, .0001). There was no differ-
ence in the proportion of females to males at either time
point (P . .05). Total number of participants from the
AIBL imaging subcohort was lower compared with the total
group. PiB-SUVR was significantly higher in the MCI and
AD groups compared with the HC group (P , .0001).
3.2. Association of biomarkers between clinical
classification at the time of collection
Comparing biomarker levels between HC and MCI
groups before adjustment for cofounders, FABP3 was signif-
icantly higher at both baseline (P 5 .00002) and 18-month
(P 5 .0001) time points, but not at 36 months (P 5 .0096)
(Table 2). This significance however was abrogated after ad-
justing for age, gender, and APOE ε4 allele status. For the
MCI versus AD group comparison, PPY stood out at
18 months, with significantly higher levels in AD compared
with MCI participants, even after adjustment for both con-
founders and multiple testing (P 5 .0001). Comparing
biomarker levels between HC and AD groups across the
three time points, 7 of 14 biomarkers measured were signif-
icantly higher in AD compared to HC at baseline and
18 months, and six biomarkers were significantly higher at
36 months. After adjustment for confounders, apoJ at base-
line and at 18 months was marginally significant after adjust-
ment for multiple comparisons (P 5 .0004). Those
associations that were not replicated at multiple time points
still showed differences between comparative groups; how-
ever, these were only significant at the nominal significance
level (without Bonferroni correction, a 5 0.05, Table 2).
3.3. Comparison of mean biomarker levels between HC
and AD groups over 36 months
Assessing mean biomarker levels over time between clin-
ical classifications (three groups, CLMM), adjusted for age,
gender, site, and APOE ε4 allele status, strongest associa-
tions were seen for I309 (P 5 .01), sVCAM (P 5 .04),
B2M (P5 .02), and ApoJ (P 5 .01), although none of these
reached the Bonferroni corrected threshold. Conducting
pairwise comparisons over time (GLMM), levels of I309
were significantly increased in AD participants compared
with MCI participants over time (P 5 .00076). Before
adjustment for covariates, levels of PPY were also higher
in AD participants compared with MCI participants over
time (P 5 .009).
3.4. Biomarker trends over time for HC and AD groups
To assess biomarker levels over time, stratified data (two
groups; only those that remained either HC (N 5 590) or
AD (N 5 109) over 36 months [stable groups]) were as-
sessed, adjusted for covariates age, gender, site, and APOE
ε4 allele status using LMM. TPO levels were significantly
decreased for the HC group (B 5 20.03 6 0.005,
P , .0001), but not for the AD (B 5 20.02 6 0.01,
P 5 .332); however, the slope was similar. CRP levels for
HC decreased (B 5 20.05 6 0.02, P 5 .05), whereas for
the AD group, they increased, albeit this was not significant
(B 5 0.14 6 0.08, P 5 .09). sVCAM1 levels in the AD
group increased over time (B5 0.036 0.01, P5 .02); how-
ever, this was not seen for the HC group (B5 0.0016 0.004,
P 5 .73). For IL-18, the decrease in biomarker levels
over time was slightly stronger for the HC group
(B 5 20.03 6 0.006, P 5 .0002) compared with the AD
group (B 5 20.02 6 0.02, P 5 .18). Both A2M and B2M
increased over time in HC and AD groups; however, rates
were slightly different, with HC mean levels for A2M
increasing more than that for the AD group (HC:
Table 1
Demographic characteristics
Baseline 18 months 36 months
P-valuesHC MCI AD HC MCI AD HC MCI AD
N 554 65 92 543 51 116 526 50 129
Age (mean SD) 69.79 (6.51) 74.84 (7.54) 77.01 (7.43) 71.12 (6.34) 76.05 (7.28) 78.68 (7.63) 72.65 (6.26) 77.56 (7.47) 80.41 (7.39) ,.0001
Gender (F/M) 330/224 36/29 52/40 328/215 23/28 67/49 318/208 25/25 73/56 ..05
APOE ε4 (2ve/1ve) 401/153 32/33 28/64 395/148 32/19 34/82 387/139 29/21 41/88 ,.0001
MMSE (median IQR) 29 (2) 27 (3) 21 (4.25) 29 (2) 27 (3) 19 (8) 29 (2) 26.5 (3) 16 (10) ,.0001
SUVR (N) 127 32 21 116 19 23 95 18 24
SUVR (mean SD) 1.36 (0.38) 2.02 (0.57) 2.29 (0.5) 1.35 (0.37) 2.03 (0.63) 2.32 (1.35) 1.38 (0.37) 1.8 (0.65) 2.43 (0.53) ,.0001
Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; SD, standard deviation; MMSE, Mini–Mental State Exam-
ination; IQR, interquartile range; SUVR, standardized uptake value ratio.
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Table 2
Cross-sectional comparisons across three clinical classifications namely HC, MCI, and AD
Time point Biomarker
Mean (SD) HC/MCI/AD HC versus MCI HC versus AD MCI versus AD
HC MCI AD Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Baseline TPO 453.72 (128.25) 486.4 (133.06) 498.25 (151.94) 0.0012 0.0356 0.0563 0.2509 0.0039 0.0502 0.5974 0.5387
IL-18 201.62 (78.55) 202.11 (99.01) 205.86 (102.95) 0.9283 0.8336 0.8567 0.7213 0.9954 0.8138 0.8969 0.5814
FABP3 6417.9 (2498.74) 7664.95 (2577.08) 7707.77 (2993.31) 2.02E208 0.3356 2.18E205 0.1285 3.41E206 0.8375 0.9936 0.4419
PPY 151.51 (123.25) 195.11 (190.74) 226.44 (153.94) 3.16E205 0.1075 0.1249 0.9325 7.56E206 0.037 0.0775 0.1454
I309 1.76 (0.89) 1.66 (0.66) 2.25 (1.43) 0.0015 0.2862 0.5181 0.117 1.13E205 0.0167 0.001 0.0066
SAA 5,014,328.58 (12,441,294.73) 4,556,617.17 (5,400,336.74) 10,066,848.34 (25,001,707.84) 0.019 0.0582 0.2092 0.2693 0.0319 0.1127 0.6153 0.6228
CRP 2,623,075.41 (5,483,161.45) 2,105,933.51 (1,992,259.53) 2,764,309.64 (5,501,614.76) 0.1497 0.9508 0.905 0.5195 0.059 0.4626 0.1728 0.4252
sVCAM 412,578.76 (93,418.88) 443,844.82 (107,111.58) 464,594.39 (118,439.3) 7.59E206 0.1634 0.012 0.3654 4.09E205 0.0855 0.3422 0.7705
sICAM 258,715.61 (57,091.32) 274,167.46 (70,100.74) 275,757.24 (57,768.89) 0.0046 0.1765 0.0524 0.3084 0.0165 0.6791 0.8869 0.9136
A2M 1,747,511,738.03 (513,469,652) 1,855,714,846.34 (602,037,583.95) 1,893,399,396.14 (581,856,370.49) 0.0062 0.4693 0.1635 0.8476 0.0101 0.4797 0.5236 0.4959
B2M 2,302,005.26 (854,220.32) 2,564,836.72 (962,444.25) 2,600,875.68 (868,669.09) 6.45E205 0.6796 0.0223 0.7112 0.0002 0.283 0.5081 0.975
fVII 855,774.28 (204,030.04) 879,676.06 (200,143.09) 870,519.29 (211,777.27) 0.33 0.4349 0.3435 0.3465 0.5341 0.8441 0.7428 0.6244
Adipo 72,058,918.21 (37,972,553.53) 85,795,000.94 (47,271,598.65) 91,367,246.13 (52,484,686.66) 9.37E206 0.0461 0.0067 0.0898 9.60E205 0.0402 0.5956 0.9282
ApoJ 34,840,490.7 (6,569,730.63) 36,905,488.48 (7,081,682.5) 38,901,971.01 (8,064,135.24) 2.70E207 0.0003 0.0183 0.0875 4.31E207 0.0004 0.1232 0.1435
18 months TPO 439.01 (124.56) 484.25 (130.48) 489.65 (168.28) 0.0005 0.0172 0.0176 0.0276 0.0034 0.0836 0.8974 0.4575
IL-18 197.31 (78.42) 202.49 (92.26) 201.59 (101.17) 0.9834 0.9396 0.8507 0.5852 0.9475 0.8877 0.86 0.4857
FABP3 6560.26 (2371.26) 7983.14 (2970.32) 7921.63 (3075.55) 3.03E209 0.2022 0.0001 0.1219 5.15E208 0.4821 0.8588 0.8237
PPY 160.98 (124.66) 164.33 (162.1) 231.27 (157.33) 3.65E205 0.0443 0.4921 0.0557 1.44E207 0.01 0.0002 0.0001
I309 1.82 (1.04) 1.72 (0.91) 2.25 (1.28) 0.0021 0.9447 0.369 0.0669 0.0001 0.1752 0.0028 0.0202
SAA 4,508,476.82 (10,011,818.68) 6,010,980.54 (13,928,739.6) 11,051,022.73 (26,601,726.7) 0.0049 0.0331 0.8312 0.8133 0.0007 0.007 0.0519 0.2179
CRP 2,324,026.89 (3,678,293.91) 3,244,249.76 (7,168,549.06) 3,750,314.02 (9,648,464.51) 0.2513 0.5808 0.8488 0.9327 0.2133 0.5945 0.5862 0.9336
sVCAM 413,866.28 (94,396.07) 451,372.28 (128,980.99) 461,761.39 (123,431.77) 3.82E205 0.5612 0.0336 0.6051 0.0001 0.5823 0.5645 0.8394
sICAM 256,940.34 (63,741.88) 276,181.68 (81,976.23) 273,854.69 (65,996.05) 0.0086 0.629 0.07 0.3302 0.022 0.8845 0.8916 0.5686
A2M 1,799,156,641.14 (533,559,105.75) 1,818,415,510.22 (540,494,569.01) 1,966,783,241.78 (593,726,925.78) 0.0051 0.6885 0.7756 0.5794 0.002 0.4514 0.097 0.1402
B2M 2,380,739.82 (906,482.97) 2,586,551.41 (1,058,022.97) 2,792,433.32 (1,002,092.54) 2.00E206 0.4936 0.1107 0.754 1.18E206 0.1792 0.1148 0.3201
fVII 859,839.14 (217,735.63) 843,890.76 (211,518.29) 904,916.05 (221,993.04) 0.1079 0.094 0.636 0.9626 0.0399 0.275 0.0974 0.3038
Adipo 73,899,317.71 (40,137,703.56) 87,609,586.8 (51,060,964.01) 89,456,380.55 (47,630,520.81) 2.76E205 0.0681 0.0197 0.0158 0.0001 0.0711 0.7607 0.399
ApoJ 35,076,852.22 (6,760,610.92) 36,935,240.02 (7,250,908.7) 39,828,311.84 (8,650,920.67) 3.59E209 0.0003 0.0635 0.1112 7.05E210 0.0004 0.0451 0.523
36 months TPO 437.79 (119.73) 463.2 (105.38) 478.3 (153.32) 0.0012 0.1789 0.1478 0.6842 0.0023 0.4755 0.5599 0.3682
IL-18 194.68 (77.96) 199.61 (97.69) 194.57 (94.75) 0.7527 0.876 0.8155 0.5699 0.6417 0.7694 0.6611 0.4462
FABP3 6953.36 (2904.37) 7988.9 (3178.54) 8026.43 (3242.37) 1.14E205 0.6319 0.0096 0.7746 0.0001 0.4757 0.8671 0.5791
PPY 162.11 (118.95) 172.88 (151.87) 228.83 (165.22) 0.0004 0.2124 0.7835 0.1079 2.56E205 0.0651 0.0111 0.0119
I309 1.91 (1.12) 1.72 (0.89) 2.29 (1.41) 0.0054 0.5469 0.1233 0.0118 0.0001 0.5706 0.0007 0.0266
SAA 6,591,850.97 (20,102,101.96) 6,152,281.83 (9,696,054.8) 11,689,850.22 (28,348,629.61) 0.0022 0.0106 0.3237 0.1837 0.0018 0.016 0.3668 0.8677
CRP 2,815,106.56 (6,320,376.91) 2,580,568.27 (3,838,300.23) 4,135,642.49 (10,667,549.77) 0.2797 0.9952 0.6139 0.9748 0.3071 0.9831 0.8702 0.8581
sVCAM 427,124.68 (103,231.67) 458,365.34 (108,775.08) 493,257.79 (138,934.86) 1.67E207 0.0134 0.0351 0.2046 1.60E207 0.0136 0.1919 0.6776
sICAM 264,728.18 (65,030.13) 273,235.93 (73,269.22) 290,037.45 (80,897.55) 0.0017 0.1356 0.406 0.624 0.001 0.3142 0.2503 0.5674
A2M 1,827,578,796.9 (545,505,679.48) 1,778,523,439.16 (433,650,399.82) 1,981,649,902.93 (624,365,511.97) 0.1339 0.6535 0.4509 0.2519 0.0359 0.6007 0.0396 0.1643
B2M 2,449,111.13 (900,460.4) 2,776,486.26 (1,441,411.42) 2,869,544.1 (1,083,739.71) 5.85E205 0.1774 0.1267 0.4804 4.51E205 0.1172 0.25 0.5588
fVII 859,473.47 (211,784.3) 828,173.72 (239,319.27) 920,802.51 (236,389.85) 0.4943 0.5917 0.3422 0.3441 0.2094 0.4345 0.1037 0.0791
Adipo 76,652,983.41 (42,470,109.59) 95,692,502.42 (128,009,842.11) 91,388,867.36 (48,296,710.64) 0.0017 0.2182 0.4015 0.358 4.92E205 0.0149 0.0003 0.0246
ApoJ 35,855,560.96 (6,862,794.16) 36,925,546.32 (7,663,254.78) 39,890,373.94 (8,623,166.76) 0.0027 0.0448 0.6585 0.752 0.001 0.0456 0.0799 0.0771
Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; SD, standard deviation; TPO, thrombopoietin; IL-18, interleukin-18; FABP3, fatty acid binding protein;
PPY, pancreatic polypeptide Y; I309, chemokine I309; SAA, serum amyloid A; CRP, C-reactive protein; sVCAM, soluble vascular adhesion molecule; sICAM, soluble intercellular adhesion molecule; A2M,
alpha-2-macroglobulin; B2M, beta-2 microglobulin; FVII, Factor VII; adipo, adiponectin; apoJ, apolipoprotein J.
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B 5 0.008 6 0.004, P 5 .03; AD: B 5 0.006 6 0.01,
P 5 .57), while the mean AD levels for B2M increased
more than that for the HC group (HC: B 5 0.001 6 0.001,
P 5 .81; AD: B 5 0.03 6 0.01, P 5 .05).
3.5. Capability of a combined biomarker model to
diagnose AD
To assess the diagnostic capability of the strongest bio-
markers for AD at each time point (found via stepwise
modeling), an ROC analysis was performed after building
a generalized linear model using APOE ε4 allele status,
age, sVCAM1, PPY, I309, apoJ, SAA, and CRP (main
effects model only) with dependent variable HC (set as 0)
and AD (set as 1). Training the model using a random
70% of the data, and testing the model on the remaining
30%, and iterating through this 100 times enabled cross-
validated prediction estimates of approximately 78%–79%
sensitivity and specificity, and AUC values at approximately
85% for all three time points. Repeating this with age,
gender, and APOE ε4 allele status only, sensitivity, speci-
ficity, and AUC values were approximately 77%, 77%, and
83%, respectively.
3.6. Cross-sectional differences between transitional,
nontransitional, and stable AD
We further grouped AIBL study participants based on the
change in clinical classification over 36 months [23]. Partic-
ipants were classified into three groups: (1) those HC that did
not transition (nontransition), (2) those who transitioned
from either HC or MCI to either MCI or AD, including
MCI participants (transition), and (3) stable AD participants
(stable AD) over the 36-month period (Table 3). Because
transitions were classed as change from baseline, statistics
from baseline are not shown. Table 4 summarizes the
cross-sectional differences in the levels of biomarkers
between different categories.
Before adjustment for confounders, biomarkers such as
PPY, I309, and B2M were able to significantly differentiate
(P , .00036) between nontransitional and stable AD
categories at both 18- and 36-month time points. At the
18-month but not at the 36-month time point, FABP3 and
apoJ were able to differentiate between nontransitional and
stable AD (P , .00036). At the 36-month but not at the
18-month time point, SAA and sVCAM were able to differ-
entiate between nontransitional and stable AD (P, .00036).
None of these associations were statistically significant after
adjustment for age, gender, and APOE ε4 allele status.
Finally, apoJ was significantly increased in the stable AD
group compared with the nontransition group at 18 months,
both before and after adjustment for confounders
(P , .00036).
Comparing biomarker levels between nontransition and
transition groups at both 18- and 36-month time points,
FABP3 and sVCAMwere significantly increased in the tran-
sition groups over the nontransition groups (P, .00036), but
only before adjustment for confounders. Adipo and PPY
were also significantly increased at the 18-month time point
in the transition group (P , .00036) compared with the
nontransition group, but only before adjustment for
confounders. Those associations that were not replicated at
multiple time points still showed differences between
comparative groups; however, these were only significant
at the nominal significance level (without Bonferroni
correction, a 5 0.05, Table 4).
3.7. Correlation with SUVR
Associations of biomarker levels with quantitative SUVR
were assessed among the participants who underwent
PiB-PET at all three collection time points showing weak-
to-moderate associations. Table 5 shows the correlation coef-
ficients (r values) from correlation analyses between SUVR
and each protein, at baseline, 18 and 36 months. There were
correlations for TPO (BL, 18M), FABP3 (BL, 18M), PPY
(BL, 18M), I309 (BL), B2M (BL), adipo (18M, 36M),
A2M (36M), and apoJ (36M) with SUVR within the MCI
subgroup. Within AD group, correlation with SUVR was
observed for FABP3 (36M) and apoJ (18M).
4. Discussion
AD is characterized by a series of pathological events.
These include amyloid b (Ab) and tau protein deposition,
oxidative damage, and inflammation, resulting in neuronal
cell death and symptoms of cognitive dysfunction. For
Table 3
Demographics table showing participants in three classifications namely nontransition, transition, and stable AD groups
18 months 36 months P-values
Nontransition Stable AD Transition Nontransition Stable AD Transition 18 months 36 months
N 520 80 79 504 78 91
Age (mean SD) 70.93 (6.23) 78.64 (7.63) 76.6 (7.62) 72.48 (6.14) 80.75 (7.24) 78.09 (7.67) ,.0001 ,.0001
Gender (F/M) 314/206 46/34 41/38 305/199 45/33 49/42 .344 .469
APOE ε4 (2ve/1ve) 375/145 23/57 40/39 366/138 23/55 45/46 ,.0001 ,.0001
MMSE (median SD) 29 (1.33) 19 (5.73) 26 (3.21) 29 (1.18) 14 (7.16) 25 (4.79) ,.0001 ,.0001
SUVR (N) 110 14 29 93 9 33
SUVR (mean SD) 1.35 (0.36) 2.26 (0.52) 2.1 (1.35) 1.39 (0.37) 2.29 (0.55) 2.07 (0.68) 1.18E218 8.64E213
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; MMSE, Mini–Mental State Examination; SUVR, standardized uptake value ratio.
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Table 4
Cross-sectional differences between transitional, nontransitional, and stable AD group
Biomarker Time point
Mean (SD) All groups
Nontransitional versus
stable AD
Nontransition versus
transition
Stable AD versus
transition
Nontransition Stable AD Transition Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
TPO 18 months 734,927.17 (915,001.31) 1,213,129.15 (1,769,353.4) 892,786.19 (910,036.55) 0.001 0.008 0.003 0.031 0.001 0.011 0.608 0.649
IL-18 18 months 785,441.3 (882,205.56) 941,067.44 (1,499,137.36) 864,354.28 (1,182,220.84) 0.851 0.780 0.848 0.703 0.843 0.596 0.955 0.647
FABP3 18 months 656,531.23 (650,406.72) 1,216,359.82 (1,600,944.1) 1,210,246.46 (1,189,060.66) 2.54E209 0.089 4.66E206 0.609 5.04E210 0.108 0.732 0.407
PPY 18 months 754,884.28 (942,461.94) 1,100,224.7 (863,039.37) 933,822.1 (1,500,440.09) 0.001 0.645 1.59E206 0.012 1.89E204 0.244 0.005 0.005
I309 18 months 745,631.85 (889,056.6) 1,177,579.61 (1,258,715.97) 742,981.38 (861,920.76) 0.037 0.307 1.16E204 0.132 0.011 0.785 0.006 0.026
SAA 18 months 725,269.34 (856,747.47) 1,220,882.21 (1,766,987.01) 892,634.17 (1,079,246.36) 0.024 0.132 0.005 0.012 0.012 0.038 0.230 0.531
CRP 18 months 802,298.22 (1,013,351.45) 756,708.33 (1,093,736.16) 931,625.38 (1,460,346.78) 0.259 0.715 0.078 0.383 0.196 0.491 0.302 0.433
sVCAM 18 months 692,349.99 (783,842.15) 1,089,117.41 (1,411,766.29) 970,385 (1,438,177.48) 1.39E204 0.695 0.001 0.580 5.73E205 0.528 0.552 0.973
sICAM 18 months 715,202.24 (925,269.56) 954,110.77 (1,174,231.67) 955,533.97 (1,243,870.25) 0.013 0.720 0.040 0.758 0.011 0.732 0.880 0.732
A2M 18 months 1,799,650,345.22 (534,498,021.57) 1,976,590,545.15 (633,002,758.16) 1,847,123,591.56 (500,192,450.05) 0.006 0.611 0.006 0.669 0.310 0.798 0.196 0.312
B2M 18 months 2,381,850.43 (907,635.57) 2,765,830.14 (965,757.82) 2,658,577.56 (1,076,595.34) 5.79E206 0.598 1.83E205 0.267 0.012 0.989 0.246 0.500
fVII 18 months 860,000.98 (217,912.04) 896,958.07 (219,752.27) 871,258.44 (219,811.81) 0.150 0.197 0.127 0.553 0.639 0.431 0.452 0.932
Adipo 18 months 73,569,851.3 (39,896,168.21) 88,122,933.79 (49,723,473.27) 91,055,858.46 (47,752,718.81) 1.36E205 0.046 0.002 0.148 1.61E204 0.002 0.505 0.124
ApoJ 18 months 35,079,670.75 (6,775,600.88) 40,217,838.62 (8,576,304.99) 37,220,101.86 (7,678,193.84) 4.58E209 2.54E204 1.11E209 2.20E204 0.012 0.072 0.020 0.151
TPO 36 months 703,881.17 (822,936.35) 1,077,448.34 (1,296,890.2) 788,618.72 (667,868.9) 0.009 0.264 0.015 0.646 0.005 0.499 0.583 0.728
IL-18 36 months 746,645.04 (858,530.23) 810,618.65 (1,376,366.07) 838,000.74 (1,111,612.79) 0.792 0.951 0.453 0.691 0.714 0.638 0.526 0.807
FABP3 36 months 822,703.27 (1,049,183.88) 981,094.25 (933,201.02) 1,201,488.19 (1,363,089.1) 5.49E205 0.855 0.006 0.292 5.38E205 0.495 0.695 0.338
PPY 36 months 781,974.64 (989,104.79) 1,151,973.57 (1,092,561.08) 954,990.77 (1,174,520.34) 0.006 0.603 1.10E204 0.059 0.002 0.445 0.046 0.054
I309 36 months 838,533.81 (1,078,746.36) 1,353,072.01 (1,746,175.95) 804,245.28 (931,700.18) 0.145 0.071 1.10E204 0.235 0.047 0.255 0.001 0.011
SAA 36 months 767,652.82 (800,384.12) 1,345,618.34 (1,628,667.49) 981,199.98 (1,443,722.11) 0.007 0.032 1.80E204 0.004 0.002 0.007 0.063 0.327
CRP 36 months 814,023.99 (954,192.13) 1,026,815.36 (1,628,202.09) 743,721.04 (864,164.17) 0.326 0.893 0.979 0.328 0.382 0.887 0.416 0.354
sVCAM 36 months 792,271.17 (881,653.84) 1,384,448.99 (1,597,444.07) 1,030,504.74 (1,333,138.23) 5.53E206 0.118 5.85E207 0.005 4.81E207 0.020 0.051 0.107
sICAM 36 months 810,655.53 (993,834.31) 1,252,178.56 (1,731,630.77) 1,025,007.5 (1,135,948.28) 0.004 0.431 0.003 0.269 0.002 0.206 0.353 0.473
A2M 36 months 1,829,309,760.37 (546,555,071.17) 1,994,538,938.13 (671,081,010.33) 1,846,566,354.11 (471,139,174.28) 0.133 0.671 0.030 0.503 0.929 0.366 0.059 0.236
B2M 36 months 2,449,468.3 (902,701.5) 2,906,874.61 (1,081,026.87) 2,732,263.3 (1,245,439.21) 9.75E205 0.181 1.34E204 0.125 0.038 0.580 0.133 0.315
fVII 36 months 858,762.71 (211,954.37) 908,875.33 (231,706.93) 888,053.93 (244,355.77) 0.524 0.574 0.242 0.613 0.760 0.678 0.238 0.182
Adipo 36 months 76,456,574.56 (42,427,744.89) 89,827,129.94 (50,476,152.8) 96,095,398.58 (98,293,155.58) 0.001 0.096 1.76E204 0.025 0.212 0.443 0.023 0.286
ApoJ 36 months 35,837,220.52 (6,875,230.87) 40,429,122.93 (8,704,482.98) 37,761,901.99 (7,900,428.96) 0.003 0.061 0.015 0.205 0.048 0.152 0.556 0.552
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; TPO, thrombopoietin; IL-18, interleukin-18; FABP3, fatty acid binding protein; PPY, pancreatic polypeptide Y; I309, chemokine I309; SAA,
serum amyloid A; CRP, C-reactive protein; sVCAM, soluble vascular adhesion molecule; sICAM, soluble intercellular adhesion molecule; A2M, alpha-2-macroglobulin; B2M, beta-2 microglobulin; FVII, Factor
VII; adipo, adiponectin; apoJ, apolipoprotein J.
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effective treatment, early diagnosis of AD is essential. How-
ever, apart from amyloid imaging, there are no established
blood biomarkers for AD. Many biomarkers reported in
the literature were limited by cohorts that were not charac-
terized specifically for AD or were the result of cross-
sectional studies. Blood-based biomarkers are considered
by many as a significant step forward to improve diagnostic
specificity and as a bridge between potential interventions
and monitoring of the disease progression.
The current selection of biomarkers has been highlighted
by previous work and warranted validation as to their useful-
ness. In this regard, we have measured their changes in the
participants of the well characterized AIBL cohort where
cognitive and lifestyle characteristics of each participant
are well documented and may be compared. This work
was undertaken to set the stage for a programmatic line of
work seeking to identify biomarkers of potential relevance
to predicting risk for future AD and current clinical diag-
nosis. Although the results from the current are internally
and not externally validated, the biomarkers investigated
were chosen on the basis that they had previously shown
some association with AD, thus by assessing each of the
markers in a large and well-characterized cohort, we have
been able to contribute to the evidence base defining their
potential use in AD prediction and diagnosis. The current
work clearly identifies signals across multiple plasma-
based biomarkers that warrant further investigation and
shows that many markers are not validated after adjustment
for disease-modifying confounders.
Initial cross-sectional analysis of our data with propor-
tional odds logistic regression revealed that 11 of the 14 tested
analyte levels changed over the 36months betweenHC,MCI,
and AD before adjustment for covariates and multiple
comparisons. The analytes that demonstrated no change
were IL-18, CRP, and FVII. After accounting for the influ-
ences of age, sex, APOE genotype, and site with the general-
ized linear model statistical method, we found that the apoJ
and I309 levels are raised in AD category compared with
HC and MCI participants, respectively, at each of the base-
line, 18- and 36-month sample times. This suggests that these
molecules might be affected or even have direct roles in the
brain as it undergoes pathological changes.
ApoJ, also known as clusterin, was initially discovered
over 20 years ago as a molecule which causes some testic-
ular cells and erythrocytes to cluster and aggregate [24]. It
appears to be associated with apoptosis in tissues that
have been injured or undergoing regression or involution
[25–29]; however, its pathological significance remains
unclear. Determining the primary function of apoJ is
complicated by its propensity to interact with a range of
molecules, including itself [30]. It has been thought of as
an extracellular heat shock protein due to the presence of
a heat shock DNA element in its promoter region [31]. It
behaves much like an extracellular version of small heat
shock proteins that chaperone misfolded proteins to remain
soluble [32]. Its expression is upregulated in many
processes including development [33], response to injury
and stress, apoptosis [34,35], and neurodegeneration [36].
Therefore, it is no surprise that we find apoJ to be signifi-
cantly increased in our AD participants compared with
their HC counterparts in all of the assessment periods. On
examination of apoJ, when the status of participants transits
Table 5
Correlation between SUVR and protein biomarkers
Biomarker All groups HC MCI AD
Baseline
TPO 0.085 0.039 0.315 20.284
IL-18 0.097 0.095 0.086 0.147
FABP3 0.186 0.068 0.522 0.242
PPY 0.21 0.116 0.345 20.011
I309 0.047 20.051 0.354 20.189
SAA 0.065 0.073 0.056 20.021
CRP 20.009 0.019 20.069 0.168
sVCAM 0.194 0.111 0.272 20.305
sICAM 0.159 0.101 0.181 0.053
A2M 0.064 0.063 0.103 20.11
B2M 0.147 0.128 0.237 20.005
fVII 0.068 0.027 0.164 0.167
Adipo 0.069 0.016 0.099 20.062
ApoJ 0.03 0.013 0.01 20.129
18 months
TPO 0.103 0.033 0.563 20.264
IL-18 0.036 20.02 0.094 0.158
FABP3 0.168 0.029 0.434 0.187
PPY 0.179 0.109 0.328 20.11
I309 0.03 20.025 0.246 20.197
SAA 20.009 20.04 0.07 0.005
CRP 20.087 20.052 20.176 0.091
sVCAM 0.141 0.041 0.012 0.024
sICAM 0.067 0.039 0.094 20.11
A2M 0.011 20.022 0.035 20.191
B2M 0.077 20.005 0.176 20.239
fVII 20.019 20.087 0.211 20.008
Adipo 0.082 0.01 0.258 20.167
ApoJ 20.006 20.026 20.023 20.294
36 months
TPO 0.082 0.072 0.066 0
IL-18 0.067 0.074 20.105 0.191
FABP3 0.113 20.012 0.21 0.399
PPY 0.116 20.008 0.197 20.139
I309 20.004 20.045 0.026 0.052
SAA 0.006 0.039 20.013 0.069
CRP 20.079 0.045 20.079 0.104
sVCAM 0.158 0.063 0.052 0.13
sICAM 0.101 0.132 20.013 0.095
A2M 20.043 20.024 0.235 20.098
B2M 0.004 0.005 0 0.02
fVII 20.115 20.097 20.279 20.163
Adipo 0.081 0.004 0.382 20.098
ApoJ 20.005 20.007 20.265 20.085
Abbreviations: SUVR, standardized uptake value ratio; HC, healthy
control; MCI, mild cognitive impairment; AD, Alzheimer’s disease;
TPO, thrombopoietin; IL-18, interleukin-18; FABP3, fatty acid binding
protein; PPY, pancreatic polypeptide Y; I309, chemokine I309; SAA,
serum amyloid A; CRP, C-reactive protein; sVCAM, soluble vascular
adhesion molecule; sICAM, soluble intercellular adhesion molecule;
A2M, alpha-2-macroglobulin; B2M, beta-2 microglobulin; FVII, Factor
VII; adipo, adiponectin; apoJ, apolipoprotein J.
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from HC to MCI or AD, it appears that this analyte does not
change markedly. These results suggest that apoJ, as
measured in the current protocols, may be most relevant
to the specific COU of detecting AD and perhaps moni-
toring progression within AD rather than the COU of
predicting future risk of AD although more work is needed.
In human plasma, this molecule is carried as a component
of high density lipoprotein (HDL) [37,38]. As a molecule in
the brain, it exists as a lower molecular weight form [39]
that is bound to HDL particles [40]. It has been identified in
noncovalent reversible complexes with soluble Ab and
some evidence suggests that it might cross the blood-brain
barrier [41,42]. The molecular weight differences between
liver-derived plasma apoJ and the astrocyte-derived form in
the brain are likely due to variation in glycosylation between
these two compartments.
This may be of functional significance for the AD brain
because intracellular forms of apoJ lack glycosylation [43]
before secretion and also appear to lack chaperone activity
[44]. These characteristics coupled with its ability to bind
a variety of molecules has led to the theory that secreted
apoJ is a molecular chaperone for extracellular misfolded
proteins [45–47]. There has been speculation that apoJ
might be a physiological carrier of Ab, and indeed, there
is evidence showing a reduction of Ab toxicity through its
sequestrating action [48]. Because of this, interest in post-
translational modification of apoJ has expanded. Although
it is known that differentially modified forms of apoJ are
made by different tissues [39,49], the significance of these
modifications are slowly being discovered [50].
Altered levels of apoJ are not only important for AD
[51–53], but also for other conditions [54,55], some of
which are linked to metabolic syndrome [56–60], another
risk factor for AD. It would be interesting to investigate
the altered apoJ levels observed between the AD and
healthy participants over time in light of post-
translational modifications. Further monitoring of our
cohort is still ongoing to gather more conclusive data.
ApoJ may yet be a useful early monitoring tool in combina-
tion with other biomarkers for cases of suspected AD.
PPY also demonstrated differences when examining our
data in those participants whose clinical status was AD.
This applied for all three periodic assessments, where the
AD group exhibited higher levels of PPY compared with
HC. This molecule has been identified in previous blood-
based biomarker investigations [3,8,9,61,62] as being
associated with MCI and AD but its role is currently
unclear. PPY is a small signaling molecule secreted by PP
cells at the periphery of Islets of Langerhans within the
pancreas and released into the circulation after a meal
[63]. The most widely accepted function for PPY is the regu-
lation of postprandial appetite suppression via actions on the
gastrointestinal tract and brain [64] via the Y4 and Y5 neu-
ropeptide receptors which initiate vagal signaling [65,66].
However, it has also been shown to control other
pancreatic secretions [67–71]. An impaired feeding
induced response from the gut that produces low levels of
PPY is associated with obesity and hyperphagia [72,73],
whereas excess PPY results in weight loss [74]. In the
AIBL cohort, the AD participants have lower averageweight
[16], suggesting that an overproduction of PPY might be a
factor. This could arise from an over stimulation of the vagal
nerve [75]. Interestingly, vagal nerve stimulation was once
considered as a treatment for AD [76] because of previously
observed improvements in cognition and depression from
this treatment [77,78]. This suggests that increased PPY
may have relationship with dietary physiology and might
be a response to AD brain pathology hence is most likely
relevant for COU of AD diagnosis.
Adipo is a protein hormone which has come to light due
to its connection with antiobesity [79] and neuroprotective
effects. It regulates many functions including inflammatory
response [80], food intake, glucose regulation [81], and fatty
acid catabolism in the periphery. It is secreted into the circu-
lation by adipose tissue as a collection of full-length species
ranging up to trimeric and larger species and even globular
form. Indeed, low levels of adipo are considered a risk factor
for metabolic syndrome [82], which itself is a risk factor for
AD. In our cohort, increased adipo levels were seen in the
AD participants over their HC counterparts at baseline and
36-month sampling periods. This increase is consistent
with previous work [83,84] which also shows that there is
some correlation in CSF. Although the 18-month period
showed a similar trend, this might suggest that the alteration
is a gradual process in response to changing brain pathology.
This may also be a response to neuroinflammation because it
is a relatively abundant anti-inflammatory adipokine which
concomitantly reduces expression of proinflammatory
cytokines [85] while increasing anti-inflammatory cytokines
[86]. This work suggests that adipo may be of most use in the
specific COU of AD diagnostics.
Among the biomarkers tested in the transition from MCI
to AD, chemokine I-309 (CCL1) was found to show the most
significant changes. This is consistent with previous work in
CSF where it was associated with cognitive decline [1] and
in other biomarker panels [9,87]. This molecule is a
glycoprotein that is secreted by activated T-lymphocytes
[88,89] and is related to a class of inflammatory cytokines
that carry the C-C motif. Its primary function appears to
be to attract monocytes, natural killer cells, immature B
cells, and dendritic cells, which all carry the necessary
CCR8 receptor [90]. It also elicits activation of monocyte
intracellular calcium mobilization as part of the immune
response [89].
Generally, chemokines are produced locally at sites of
inflammation or infection to regulate recruitment of other
immune cells such as leukocytes and lymphocytes. The
consistent increase of I-309 in the MCI-AD transition partic-
ipants could indicate increasing brain injury or pathology.
Chemokines are typically released by endothelial cells on
stimulation by inflammatory cytokines [91–93], but I-309
is unusual because it is released by the more mobile
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T-lymphocytes, which could suggest a wider immune
response from the body. One of the possible effects may
be to attract immune cells to injured areas, such as to help
clear away amyloid as seen in studies of the similar CCL2
receptor [94]. The current data suggest that plasma I-309
levels may be most useful in the COU of detecting AD
and distinguishing AD from MCI. Interestingly, we also
find it to be changed significantly in those who underwent
transition from MCI to AD over all three test periods. It is
possible that specific alterations of I-309 at specific time
points may also be indicative of imminent likelihood of
transition from MCI to AD.
sVCAM1 belongs to a class of cell adhesion molecules
(CAMs), binding proteins that appear to be important in
inflammatory or injury processes involving the endothelium
and blood cells, such as platelets. These soluble molecules
are generally present in the circulation near sites of injury to
the endothelium, such as an atherosclerotic plaque [95–99].
After cytokine activation, CAMS are released into the
circulation, which may then be detected. It has been
reported that measurement of these molecules could be
useful in diagnosis of cardiovascular injury [100–103].
When comparing the HC with AD participants, sVCAM
did not change markedly until 36 months in our study.
This delay might indicate that sVCAM might be a
reparatory physiological response to injury and
inflammation, rather than an initiator that directly
influences the pathology because it is upregulated in
endothelial cells that have been stimulated by cytokines
[104]. It mediates the adhesion of lymphocytes, monocytes,
eosinophils, and basophils to the vasculature [105,106] and
is implicated in the early stages of atherosclerosis [107].
This suggests that peripheral vascular injury contributes
to the pathology of the AD-affected brain. Further follow-
up examinations of the cohort would help to shed more light
on the physiological processes involved.
There are significant advantages of the present study
over much prior work. First, the current work examined
longitudinal change in multiple previously identified poten-
tial AD blood-based biomarkers. In addition, the sample
size is significantly larger than much prior work and the
deep phenotypic characterization of the AIBL cohort is
an additional advantage. In the current work, multiple
biomarkers were examined longitudinally to identify a set
of markers for further examination in the COU of
diagnosing and predicting future risk of AD. In this
work, multiple markers were supported as potential diag-
nostic AD biomarkers while others were only likely useful
for future risk prediction. As was pointed out recently by
an international working group (including the current
team), the first step in moving biomarker discovery to
potential clinical use is the identification and initial support
of the biomarkers within the specific COU. The current
work addresses that first step and sets the stage for move-
ment toward (1) additional replication of these biomarkers
(individually and in combination) as well as (2) discovery
of additional biomarkers of relevance to this specific COU.
The AIBL cohort provides a unique cohort for these next
steps, which will then be replicated across independent
cohorts.
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RESEARCH IN CONTEXT
1. Systematic review: Blood biomarkers have attracted
a great deal of attention in recent times in regards to
early diagnosis and monitoring of Alzheimer’s dis-
ease (AD); however, there is a huge inconsistency
in the field.
2. Interpretation: We have used plasma samples from
the Australian Imaging, Biomarkers and Lifestyle
(AIBL) Study of Ageing cohort to specifically
answer the question if plasma protein biomarkers
can be used for diagnostic accuracy. Our results
show that levels of I309 and PPY were significantly
increased in AD participants compared with MCI
participants over time. We also showed apolipopro-
tein J to be increased in AD patients compared
with healthy participants longitudinally.
3. Future directions: The current work addresses that
first step and sets the stage for movement towards
(1) additional replication of these biomarkers (indi-
vidually and in combination) as well as (2) discovery
of additional biomarkers of relevance to this specific
COU. The AIBL cohort provides a unique cohort for
these next steps, which will then be replicated across
independent cohorts.
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